These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11925325)

  • 1. Early-stage vision and schizophrenia.
    Kéri S; Janka Z; Benedek G
    Am J Psychiatry; 2002 Apr; 159(4):678; author reply 678-9. PubMed ID: 11925325
    [No Abstract]   [Full Text] [Related]  

  • 2. [The Spatial-Frequency Characteristics of the Visual System in Schizophrenia].
    Shoshina II; Shelepin YE; Vershinina EA; Novikova KO
    Fiziol Cheloveka; 2015; 41(3):29-40. PubMed ID: 26237946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visual perception in medicated schizophrenic patients.
    Schwartz B; Winstead DK
    Am J Psychiatry; 1997 Apr; 154(4):585-7. PubMed ID: 9090363
    [No Abstract]   [Full Text] [Related]  

  • 4. Visual masking in schizophrenia: overview and theoretical implications.
    Green MF; Lee J; Wynn JK; Mathis KI
    Schizophr Bull; 2011 Jul; 37(4):700-8. PubMed ID: 21606322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The frequency-contrast sensitivity of visual stimulus perception in patients with schizophrenia with the therapy of atypical and typical antipsychotic drugs].
    Shoshina II; Shelepin IuE; Semenova NB
    Fiziol Cheloveka; 2014; 40(1):43-8. PubMed ID: 25272767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first-episode schizophrenia.
    Keedy SK; Rosen C; Khine T; Rajarethinam R; Janicak PG; Sweeney JA
    Psychiatry Res; 2009 Apr; 172(1):16-23. PubMed ID: 19243925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visual perception and its impairment in schizophrenia.
    Butler PD; Silverstein SM; Dakin SC
    Biol Psychiatry; 2008 Jul; 64(1):40-7. PubMed ID: 18549875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blunted inhibition of return in schizophrenia-evidence from a longitudinal study.
    Gouzoulis-Mayfrank E; Heekeren K; Voss T; Moerth D; Thelen B; Meincke U
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):389-96. PubMed ID: 14751438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrast sensitivity and magnocellular functioning in schizophrenia.
    Skottun BC; Skoyles JR
    Vision Res; 2007 Oct; 47(23):2923-33. PubMed ID: 17825350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High and low dose thiothixene treatment in chronic schizophrenia.
    Gardos G; Orzack MH; Finn G; Cole JO
    Dis Nerv Syst; 1974 Feb; 35(2):53-8. PubMed ID: 17894041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paroxysmal perceptual alteration in a schizophrenic patient treated with paliperidone: A case report.
    Benna P; Rubino E; Marino C; Montalenti E; Giovanna Caprioli M; Rainero I; Pinessi L
    Ann Clin Psychiatry; 2015 Aug; 27(3):223-4. PubMed ID: 26247222
    [No Abstract]   [Full Text] [Related]  

  • 12. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Modification of visual perception by vision training].
    Nemetz U; Harrer S
    Klin Monbl Augenheilkd; 1987 Feb; 190(2):83-91. PubMed ID: 3573667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visual perception in medicated schizophrenic patients.
    Bonnet D; Chabrol H
    Am J Psychiatry; 1997 Apr; 154(4):585; author reply 586-7. PubMed ID: 9090362
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopaminergic modulation of visual attention and working memory in the rodent prefrontal cortex.
    Chudasama Y; Robbins TW
    Neuropsychopharmacology; 2004 Sep; 29(9):1628-36. PubMed ID: 15138446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine and schizophrenia.
    Crow TJ; Johnstone EC; Longden A; Owen F
    Adv Biochem Psychopharmacol; 1978; 19():301-9. PubMed ID: 29450
    [No Abstract]   [Full Text] [Related]  

  • 17. Prediction of outcome in first-episode schizophrenia.
    Lieberman JA
    J Clin Psychiatry; 1993 Mar; 54 Suppl():13-7. PubMed ID: 8097192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A few remarks on attention and magnocellular deficits in schizophrenia.
    Skottun BC; Skoyles JR
    Neurosci Biobehav Rev; 2008; 32(1):118-22. PubMed ID: 17651801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reliability and clinical correlates of figure-ground perception in schizophrenia.
    Malaspina D; Simon N; Goetz RR; Corcoran C; Coleman E; Printz D; Mujica-Parodi L; Wolitzky R
    J Neuropsychiatry Clin Neurosci; 2004; 16(3):277-83. PubMed ID: 15377734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Necessity of novel single-antipsychotic-agent therapies for acute phase of schizophrenia].
    Tsutsumi Y
    Seishin Shinkeigaku Zasshi; 2006; 108(6):619-23. PubMed ID: 16910540
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.